High-purity raw materials and formulation-ready intermediates manufactured under strict cGMP standards.
A comprehensive analysis of vasoprotective pharmacology, microvascular hyperpermeability regulation, and OEM production standards.
Calcium Dobesilate (Calcium 2,5-dihydroxybenzenesulfonate monohydrate, CAS: 20123-80-2) is a synthetic vasoprotective agent widely prescribed for microvascular disorders. Its unique structure acts directly on capillary walls to restore normal physiological function without exerting systemically disruptive hemodynamic actions.
By neutralizing reactive oxygen species (ROS), inhibiting platelet-activating factor (PAF) synthesis, and suppressing thrombocyte aggregation, Calcium Dobesilate drastically reduces endothelial dysfunction. It inhibits capillary hyperpermeability, decreases blood viscosity, and improves lymphatic drainage—making it the gold-standard therapeutic choice for diabetic retinopathy, chronic venous insufficiency (CVI), and hemorrhoidal syndrome.
Gentolex operates scalable chemical synthesis facilities designed to manufacture Calcium Dobesilate API with absolute batch-to-batch consistency. Below is our standard analytical specification compliance for commercial supply:
| Analytical Test Parameter | Pharmacopoeial Requirement (EP / USP / ChP) | Gentolex High-Purity OEM Grade Standard | Testing Methodology |
|---|---|---|---|
| Assay Content | 98.0% - 102.0% | 99.2% - 100.8% | Potentiometric Titration / HPLC |
| Hydroquinone Impurity | ≤ 0.2% (2000 ppm) | ≤ 0.001% (< 10 ppm) | HPLC-UV (Reverse Phase) |
| Water Content (Karl Fischer) | 4.0% - 6.0% | 4.2% - 5.2% | Volumetric Karl Fischer Titration |
| Sulfated Ash / Residue | 17.0% - 19.0% | 17.5% - 18.5% | Gravimetric Residue Test |
| Heavy Metals (Pb, Cd, As, Hg) | ≤ 20 ppm Total | ≤ 5 ppm (ICP-MS Tested) | ICP-MS Method |
| Microbial Enumeration | TAMC < 1000 CFU/g | TAMC < 100 CFU/g | No E. Coli / Salmonella | Microbiological Membrane Filtration |
Strategic analysis of microvascular health therapeutics and global supply chain requirements for pharmaceutical brand owners.
With global diabetes prevalence expected to surpass 700 million adults by 2045, diabetic microvascular complications are escalating rapidly. OEM demand for raw Calcium Dobesilate has risen by 8.4% CAGR globally. Formulators require high-solubility APIs capable of meeting stringent stability tests under Zone IV humid climatic conditions.
Chronic Venous Insufficiency (CVI) impacts over 30% of the adult population worldwide. Calcium Dobesilate oral solid dosages (500mg capsules and tablets) remain primary treatment options. OEM buyers seek integrated CDMO partners who can supply both raw API and license out validated Finished Dosage Form (FDF) dossiers.
Pharma procurement managers prioritize suppliers offering complete regulatory protection: CEP/COS certificates, US FDA DMF filings, and EDQM compliance. Gentolex maintains robust supply continuity, multi-ton synthesis facilities, and localized customer support hubs in Mexico and South Africa.
Innovative synthetic routes, strict impurity isolation, and advanced formulation technology.
The conventional sulfonation of hydroquinone often yields toxic residual hydroquinone impurities and unstable color degradation in finished dosage forms. Gentolex's proprietary green chemistry process utilizes catalytic sulfonation under inert nitrogen purging.
Our multi-stage recrystallization protocol systematically reduces residual hydroquinone levels to < 10 ppm, well below standard pharmacopoeial thresholds. This prevents oxidative discolouration, extending the shelf-life of finished tablets and capsules to 36+ months.
To optimize oral absorption and reduce gastrointestinal side effects, our CDMO division offers specialized particle micronization and microencapsulation. We engineer customized bulk density and particle size distribution (PSD) profiles tailored to direct-compression tablet manufacturing.
Furthermore, our technical team provides sustained-release matrix development, allowing for 24-hour therapeutic coverage with once-daily dosing regimens for improved patient compliance.
Connecting the world with guaranteed pharmaceutical products, peptide engineering, and full-service procurement solutions.
Gentolex's goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specifically establishing dedicated regional offices in Mexico and South Africa to ensure flawless local support, customs clearance assistance, and just-in-time delivery.
Our main services focus on supplying high-purity small molecule APIs, peptide APIs, Custom Peptides synthesis, Finished Dosage Form (FDF) license-out, Technical Support & Consultation, Product Line and Lab Setup, as well as Turnkey Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective chemical solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported worldwide.
Comprehensive R&D services from bench-scale synthesis to commercial formulation optimization and FDF license-out packages.
For clients preferring to avoid dealing with multiple points of contact, we provide customized procurement services with superior supply chain resources.
Our production lines adhere to WHO-GMP, EU-GMP, US-FDA, and ISO quality management guidelines.
Stay updated with our latest scientific research, peptide developments, and API production breakthroughs.
Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Originally developed through neuropharmacological research, Selank represents high-demand neuroactive peptide solutions...
Read Article
As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Tβ4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and commercial scale peptide syntheses globally...
Read Article
BPC-157 API is a synthetic pentadecapeptide gaining global attention in tissue repair, gastrointestinal mucosal protection, and anti-inflammatory pathways. We offer industrial bulk manufacturing under strict analytical control...
Read Article
With the continuous development of neuroscience and peptide R&D, Semax has emerged as an essential ACTH-derived fragment. Discover our synthesis technologies and purity profiles for worldwide export...
Read Article
SS-31 API (Elamipretide / MTP-131 / Bendavia) is a mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane, supporting cellular bioenergetics and therapeutic research...
Read ArticleDetailed technical answers to common queries raised by pharmaceutical buyers, regulatory officers, and formulators.
Explore our broader portfolio of peptide intermediates, surfactants, and specialized pharmaceutical ingredients.
